Jeffrey K Aronson
MA DPhil FRCP HonFBPhS HonFFPM
Consultant Physician and Clinical Pharmacologist
Research
- Methods of classifying, detecting, and reporting adverse drug reactions, including systematic reviews, meta-analyses, and the use of anecdotal reports
- Innovation in drug therapy
- Monitoring therapy in chronic disease
- Systematic reviews of pharmacokinetics, pharmacodynamics, and pharmacokinetic–pharmacodynamic modelling
- The role of mechanisms in the philosophy of evidence-based medicine
- Linguistic aspects of medicine and pharmacology
Teaching and training
- Teaching medical students the fundamentals of therapeutics.
- Ad hoc two-week special study modules in clinical pharmacology and therapeutics for medical students.
- Co-author of didactic textbooks (e.g. “The Oxford Handbook of Practical Drug Therapy”) and contributor of chapters to others.
- Editor, Meyler’s Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions (16th edition, 2015) and of its annual updates, Side Effects of Drugs Annuals 1-35
- Co-editor (with John Talbot), Stephens’ Detection and Evaluation of Adverse Drug Reactions: Principles and Practice. 6th edition
Policy
- President Emeritus, Honorary Fellow, and past Vice-President Publications, British Pharmacological Society.
- Previous Member of the Advisory Board of the British National Formulary.
- Chairman of the British Pharmacopoeia Commission’s Expert Advisory Group on Nomenclature
- Member, WHO’s Expert Advisory Panel on International Pharmacopoeia and Pharmaceutical Preparations
Key publications
-
Quantifying the effects of diuretics and β-adrenoceptor blockers on glycaemic control in diabetes mellitus - A systematic review and meta-analysis
Journal article
Hirst JA. et al, (2015), British Journal of Clinical Pharmacology, 79, 733 - 743
-
The law of mass action and the pharmacological concentration-effect curve: Resolving the paradox of apparently non-dose-related adverse drug reactions
Journal article
(2016), British Journal of Clinical Pharmacology, 81, 56 - 61
-
Joining the DoTS: new approach to classifying adverse drug reactions.
Journal article
Aronson JK. and Ferner RE., (2003), BMJ, 327, 1222 - 1225
-
EIDOS: a mechanistic classification of adverse drug effects.
Journal article
Ferner RE. and Aronson JK., (2010), Drug Saf, 33, 15 - 23
-
Toward standardized reporting of drug interactions: The READI checklist for anecdotal reports
Journal article
(2015), Expert Review of Clinical Pharmacology, 8, 399 - 409
-
The need for randomization in animal trials: An overview of systematic reviews
Journal article
Hirst JA. et al, (2014), PLoS ONE, 9
-
Can understanding mechanisms solve the problem of extrapolating from study to target populations (the problem of 'external validity')?
Journal article
(2013), Journal of the Royal Society of Medicine, 106, 81 - 86
-
Distinguishing hazards and harms, adverse drug effects and adverse drug reactions : implications for drug development, clinical trials, pharmacovigilance, biomarkers, and monitoring.
Journal article
Aronson JK., (2013), Drug Saf, 36, 147 - 153
-
A new taxonomy for describing and defining adherence to medications
Journal article
(2012), British Journal of Clinical Pharmacology, 73, 691 - 705
-
Drug shortages. Part 1. Definitions and harms.
Journal article
Aronson JK. et al, (2023), Br J Clin Pharmacol
Recent publications
-
When I use a word . . . Love drugs.
Journal article
Aronson JK., (2024), BMJ, 386
-
When I use a word . . . The languages of medicines-defining a street drug operationally.
Journal article
Aronson JK., (2024), BMJ, 385
-
When I use a word . . . The languages of medicines—street drugs
Journal article
Aronson JK., (2024), BMJ, q1391 - q1391
-
An analysis of international strategies for monitoring and preventability described in medicinal product information: a study protocol
Preprint
Sartori D. et al, (2024)
-
When I use a word . . . The languages of medicines-umbrella terms.
Journal article
Aronson JK., (2024), BMJ, 385
-
When I use a word . . . The languages of medicines-US proprietary names.
Journal article
Aronson JK., (2024), BMJ, 385
-
Preventable suicides involving medicines: A systematic case series of coroners’ reports in England and Wales
Journal article
Anthony G. et al, (2024), Public Health in Practice, 7
-
When I use a word . . . The languages of medicines-trade names, proprietary names, or brand-names.
Journal article
Aronson JK., (2024), BMJ, 385
-
When I use a word . . . The languages of medicines-International Nonproprietary Names (INNs).
Journal article
Aronson JK., (2024), BMJ, 385
-
When I use a word . . . The languages of medicines—generics and bioavailability
Journal article
Aronson JK., (2024), BMJ, q1064 - q1064